About Us

About Us

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) is our lead product in development, and has completed pivotal Phase 3 clinical trials. We have licensed North American rights to bremelanotide to AMAG Pharmaceuticals, Inc. and Chinese rights to bremelanotide to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. We have development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis.